REDWOOD CITY, Calif., August 4, 2009 — Satoris, Inc., a California-based molecular diagnostics company, announced today that it has been appointed by Rules-Based Medicine, Inc. (RBM), the world’s leading multiplexed biomarker testing laboratory, as the global distributor of RBM’s DiscoveryMAPTM panel for neurology research. This new development will allow neurology researchers and pharmaceutical companies developing new therapies to access any of four service-based biomarker panels from a single source. In June, Satoris launched three of its own biomarker panels which include a Dementia Discrimination panel to aid in differentiating patients suffering from Alzheimer’s from those with other forms of dementia, and the Neuro61 and Neuro77 panels for plasma proteins associated with neurodegeneration and neuroinflammation.
The RBM DiscoveryMAPTM is a 189-biomarker panel that covers the most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development. It can thus provide researchers with critical biological information plus leads for further study.
Drug developers are becoming more aware of the value of biomarkers for increasing efficiency and reducing the cost and risk associated with research studies and clinical trials. Researchers require quantitative data to identify the biomarker patterns that are either directly involved in the disease process or are useful surrogate markers. When these patterns can be reliably measured, the efficiency of drug development is accelerated and greater efficacy and safety are achieved.
“We are very pleased to be partnering with RBM in making this comprehensive panel of protein biomarkers available to neurology researchers,” said Cris McReynolds, President and CEO of Satoris. “DiscoveryMAPTM is an exceptionally broad panel of analytes designed specifically to enable researchers to understand their compound’s efficacy, safety, and biological activity, and it is complementary to our existing biomarker panels. By quantifying nearly 200 important blood proteins, DiscoveryMAP™ will be an important tool in accelerating research on Alzheimer’s disease and related neurodegenerative disorders.”
About Satoris Service-Based Biomarker Panels
The Neuro61 Biomarker Panel and Neuro77 Biomarker Panels detect plasma proteins most likely associated with neurodegeneration and neuroinflammation and which, based on the analysis of 3300 patient samples, have been identified as significant in Alzheimer’s and dementia. The Satoris Dementia Discrimination Panel comprises 12 protein markers that can aid clinical researchers involved in Alzheimer’s disease characterization and in the development of treatment methods.
About Satoris
Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a molecular diagnostics company focused on developing blood-based tests for Alzheimer’s disease. For more information see http://www.satorisinc.com.
About Rules-Based Medicine
Rules-Based Medicine (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The proprietary Multi-Analyte Profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. The RBM approach to biomarker testing delivers analytical and financial advantages and is changing the way therapeutics are developed, people are diagnosed and patients are treated. Find out more at www.rulesbasedmedicine.com.
The RBM DiscoveryMAPTM is a 189-biomarker panel that covers the most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development. It can thus provide researchers with critical biological information plus leads for further study.
Drug developers are becoming more aware of the value of biomarkers for increasing efficiency and reducing the cost and risk associated with research studies and clinical trials. Researchers require quantitative data to identify the biomarker patterns that are either directly involved in the disease process or are useful surrogate markers. When these patterns can be reliably measured, the efficiency of drug development is accelerated and greater efficacy and safety are achieved.
“We are very pleased to be partnering with RBM in making this comprehensive panel of protein biomarkers available to neurology researchers,” said Cris McReynolds, President and CEO of Satoris. “DiscoveryMAPTM is an exceptionally broad panel of analytes designed specifically to enable researchers to understand their compound’s efficacy, safety, and biological activity, and it is complementary to our existing biomarker panels. By quantifying nearly 200 important blood proteins, DiscoveryMAP™ will be an important tool in accelerating research on Alzheimer’s disease and related neurodegenerative disorders.”
About Satoris Service-Based Biomarker Panels
The Neuro61 Biomarker Panel and Neuro77 Biomarker Panels detect plasma proteins most likely associated with neurodegeneration and neuroinflammation and which, based on the analysis of 3300 patient samples, have been identified as significant in Alzheimer’s and dementia. The Satoris Dementia Discrimination Panel comprises 12 protein markers that can aid clinical researchers involved in Alzheimer’s disease characterization and in the development of treatment methods.
About Satoris
Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a molecular diagnostics company focused on developing blood-based tests for Alzheimer’s disease. For more information see http://www.satorisinc.com.
About Rules-Based Medicine
Rules-Based Medicine (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The proprietary Multi-Analyte Profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. The RBM approach to biomarker testing delivers analytical and financial advantages and is changing the way therapeutics are developed, people are diagnosed and patients are treated. Find out more at www.rulesbasedmedicine.com.
